Sotera Health upgraded to Buy from Hold at Jefferies

Jefferies upgraded Sotera Health to Buy from Hold with a price target of $15.50, up from $15. The analyst sees a turn in three areas that weighed on Sotera for the last 18 months. The firm expects strong medical technology volumes pulling through to Steri and Nelson, a life science macro recovery, and moderating interest rates. LifeSci is at historical growth and could drive material upside, the analyst tells investors in a research note. On litigation, Jefferies said the stock overreacted to the Los Angeles lawsuit, based on its work. It views the stock’s rent selloff as overdone.